67 related articles for article (PubMed ID: 15756276)
1. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
McQuade JL; Posada LP; Lecagoonporn S; Cain S; Bassett RL; Patel SP; Hwu WJ; Hwu P; Davies MA; Bedikian AY; Amaria RN
Melanoma Res; 2016 Dec; 26(6):604-608. PubMed ID: 27540836
[TBL] [Abstract][Full Text] [Related]
2. A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules.
Ducray F; Ramirez C; Robert M; Fontanilles M; Bronnimann C; Chinot O; Estrade F; Durando X; Cartalat S; Bastid J; Bienayme H; Lemarchand C
Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140005
[TBL] [Abstract][Full Text] [Related]
3. Topical Cream Carrying Drug-Loaded Nanogels for Melanoma Treatment.
Rahman S; Haque TN; Sugandhi VV; Saraswat AL; Xin X; Cho H
Pharm Res; 2023 Oct; 40(10):2291-2301. PubMed ID: 37012533
[TBL] [Abstract][Full Text] [Related]
4. Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity.
Doan P; Nguyen P; Murugesan A; Candeias NR; Yli-Harja O; Kandhavelu M
Cells; 2021 Aug; 10(8):. PubMed ID: 34440745
[TBL] [Abstract][Full Text] [Related]
5. Thermoresponsive nanocomposite gel for local drug delivery to suppress the growth of glioma by inducing autophagy.
Ding L; Wang Q; Shen M; Sun Y; Zhang X; Huang C; Chen J; Li R; Duan Y
Autophagy; 2017 Jul; 13(7):1176-1190. PubMed ID: 28594260
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells.
Ling B; Michel D; Sakharkar MK; Yang J
Drug Des Devel Ther; 2016; 10():3563-3572. PubMed ID: 27843296
[TBL] [Abstract][Full Text] [Related]
7. The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells.
Xu Y; Shen M; Li Y; Sun Y; Teng Y; Wang Y; Duan Y
Oncotarget; 2016 Apr; 7(15):20890-901. PubMed ID: 26956046
[TBL] [Abstract][Full Text] [Related]
8. In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.
McDermott M; Eustace AJ; Busschots S; Breen L; Crown J; Clynes M; O'Donovan N; Stordal B
Front Oncol; 2014; 4():40. PubMed ID: 24639951
[TBL] [Abstract][Full Text] [Related]
9. Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
Vellimana AK; Recinos VR; Hwang L; Fowers KD; Li KW; Zhang Y; Okonma S; Eberhart CG; Brem H; Tyler BM
J Neurooncol; 2013 Feb; 111(3):229-36. PubMed ID: 23224713
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.
Ott PA; Hamilton A; Jones A; Haas N; Shore T; Liddell S; Christos PJ; Doyle LA; Millward M; Muggia FM; Pavlick AC
PLoS One; 2010 Jan; 5(1):e8714. PubMed ID: 20098694
[TBL] [Abstract][Full Text] [Related]
11. A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents.
Braun TM; Wang S
Biometrics; 2010 Sep; 66(3):805-12. PubMed ID: 19995354
[TBL] [Abstract][Full Text] [Related]
12. Genetic similarity and hatching success in birds.
Spottiswoode C; Møller AP
Proc Biol Sci; 2004 Feb; 271(1536):267-72. PubMed ID: 15058437
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
Movva S; Verschraegen CF; Rabinowitz I; Mangalik A; Parks V; Lee FC
Melanoma Res; 2011 Feb; 21(1):76-9. PubMed ID: 21169871
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
Alrwas A; Papadopoulos NE; Cain S; Patel SP; Kim KB; Deburr TL; Bassett R; Hwu WJ; Bedikian AY; Davies MA; Woodman SE; Hwu P
Melanoma Res; 2014 Aug; 24(4):342-8. PubMed ID: 24743052
[TBL] [Abstract][Full Text] [Related]
15. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Ott PA; Chang J; Madden K; Kannan R; Muren C; Escano C; Cheng X; Shao Y; Mendoza S; Gandhi A; Liebes L; Pavlick AC
Cancer Chemother Pharmacol; 2013 Jan; 71(1):183-91. PubMed ID: 23064957
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Su Y; Amiri KI; Horton LW; Yu Y; Ayers GD; Koehler E; Kelley MC; Puzanov I; Richmond A; Sosman JA
Clin Cancer Res; 2010 Jan; 16(1):348-57. PubMed ID: 20028756
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Bafaloukos D; Gogas H; Georgoulias V; Briassoulis E; Fountzilas G; Samantas E; Kalofonos Ch; Skarlos D; Karabelis A; Kosmidis P
J Clin Oncol; 2002 Jan; 20(2):420-5. PubMed ID: 11786569
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.
Azzabi A; Hughes AN; Calvert PM; Plummer ER; Todd R; Griffin MJ; Lind MJ; Maraveyas A; Kelly C; Fishwick K; Calvert AH; Boddy AV
Br J Cancer; 2005 Mar; 92(6):1006-12. PubMed ID: 15756276
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
